Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial.
METHODS
The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL (LDLox), apolipoprotein-B (ApoB), and serum lipids on statin-treated patients in primary cardiovascular disease prevention (PCP).


RESULTS
A triple-blind, randomized, placebo-controlled trial was conducted. Seventy-five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol-enriched grape extract (GE-RES, Stilvid®), grape extract (GE, similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol (LDLc) decreased by 2.9% (p = 0.013) in the GE group. In contrast, LDLc (-4.5%, p = 0.04), ApoB (-9.8%, p = 0.014), LDLox (-20%, p = 0.001), and LDLox/ApoB (-12.5%, p = 0.000) decreased in the Stilvid® group, whereas the ratio non-HDLc (total atherogenic cholesterol load)/ApoB increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients.


CONCLUSIONS
This GE-RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold-standard medication in patients from PCP. The presence of resveratrol in the GE was necessary to achieve these effects.
Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, Murcia, Spain.
Joao
J
Tomé-Carneiro
Manuel
M
Gonzálvez
Mar
M
Larrosa
Francisco J
FJ
García-Almagro
Francisco
F
Avilés-Plaza
Soledad
S
Parra
María J
MJ
Yáñez-Gascón
José A
JA
Ruiz-Ros
María T
MT
García-Conesa
Francisco A
FA
Tomás-Barberán
Juan Carlos
JC
Espín
D000368:Aged; D001055:Apolipoproteins B / Q000097:blood*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D019587:Dietary Supplements; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000494:pharmacology; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013960:Thyroid Function Tests; D027843:Vitis / Q000737:chemistry
D001055:Apolipoproteins B; D008055:Lipids; D008077:Lipoproteins, LDL; D010936:Plant Extracts; D013267:Stilbenes; C099252:oxidized low density lipoprotein; D000077185:Resveratrol